Prof. Danilo Toni discusses findings from the RE-AFFIRM study for patients with prior stroke treated with Rivaroxaban vs. Warfarin in clinical routine and puts the data from the randomized controlled trial ROCKET AF into perspective
© Bayer AG, 2020 | Approval number PP-XAR-ALL-1767-1